A Phase 2, Open Label Extension Study To Investigate The Long Term Safety And Tolerability Of Pf-06649751 In Subjects With Motor Fluctuations Due To Parkinson's Disease
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs PF 6649751 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 03 Oct 2017 Planned End Date changed from 27 Jan 2020 to 1 Oct 2020.
- 03 Oct 2017 Planned primary completion date changed from 27 Jan 2020 to 1 Oct 2020.
- 31 Jul 2017 Status changed from not yet recruiting to recruiting.